JP2002537258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002537258A5 JP2002537258A5 JP2000599393A JP2000599393A JP2002537258A5 JP 2002537258 A5 JP2002537258 A5 JP 2002537258A5 JP 2000599393 A JP2000599393 A JP 2000599393A JP 2000599393 A JP2000599393 A JP 2000599393A JP 2002537258 A5 JP2002537258 A5 JP 2002537258A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- vivo
- formula
- hypertension
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001727 in vivo Methods 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 201000004239 Secondary hypertension Diseases 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 208000002815 pulmonary hypertension Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- -1 benzazepine-N-acetic acid compound Chemical class 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical class OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 0 *CC(C*)(CC(*)*)*NC(CCc1ccccc1N1C*)C1=O Chemical compound *CC(C*)(CC(*)*)*NC(CCc1ccccc1N1C*)C1=O 0.000 description 1
- QJJDBWAEIBNZPQ-UHFFFAOYSA-N 2-(3h-1,2-benzothiazepin-2-yl)acetic acid Chemical class S1N(CC(=O)O)CC=CC2=CC=CC=C21 QJJDBWAEIBNZPQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- DGMPBKBFGAHVJV-UHFFFAOYSA-N O1N(CC=CC2=C1C=CC=C2)CC(=O)O Chemical class O1N(CC=CC2=C1C=CC=C2)CC(=O)O DGMPBKBFGAHVJV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906310A DE19906310A1 (de) | 1999-02-16 | 1999-02-16 | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19906310.9 | 1999-02-16 | ||
| PCT/EP2000/001068 WO2000048601A1 (de) | 1999-02-16 | 2000-02-10 | Arzneimittel zur behandlung von bluthochdruck |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002537258A JP2002537258A (ja) | 2002-11-05 |
| JP2002537258A5 true JP2002537258A5 (enExample) | 2011-08-25 |
Family
ID=7897580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000599393A Pending JP2002537258A (ja) | 1999-02-16 | 2000-02-10 | 高血圧の治療のための医薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6482820B2 (enExample) |
| EP (1) | EP1154777B1 (enExample) |
| JP (1) | JP2002537258A (enExample) |
| KR (2) | KR100797665B1 (enExample) |
| CN (1) | CN1198619C (enExample) |
| AR (1) | AR036864A1 (enExample) |
| AT (1) | ATE295174T1 (enExample) |
| AU (1) | AU773240C (enExample) |
| BR (1) | BR0008260A (enExample) |
| CA (1) | CA2362273C (enExample) |
| CZ (1) | CZ301499B6 (enExample) |
| DE (2) | DE19906310A1 (enExample) |
| DZ (1) | DZ3014A1 (enExample) |
| ES (1) | ES2238268T3 (enExample) |
| HK (1) | HK1042247B (enExample) |
| HU (1) | HUP0105491A3 (enExample) |
| IL (1) | IL144622A (enExample) |
| NO (1) | NO329588B1 (enExample) |
| NZ (1) | NZ514058A (enExample) |
| PL (1) | PL195283B1 (enExample) |
| PT (1) | PT1154777E (enExample) |
| RU (1) | RU2270679C2 (enExample) |
| SK (1) | SK287254B6 (enExample) |
| TR (1) | TR200102386T2 (enExample) |
| TW (1) | TWI221770B (enExample) |
| UA (1) | UA63032C2 (enExample) |
| WO (1) | WO2000048601A1 (enExample) |
| ZA (1) | ZA200105828B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| CA2392076A1 (en) * | 1999-11-19 | 2001-05-25 | Solvay Pharmaceuticals B.V. | Human enzymes of the metalloprotease family |
| CA2357833C (en) * | 2000-10-04 | 2005-11-15 | Warner-Lambert Company | Treatment of pulmonary hypertension using vasopressin antagonist |
| PL367093A1 (en) * | 2001-05-18 | 2005-02-21 | Solvay Pharmaceuticals Gmbh | Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments |
| PL224030B1 (pl) * | 2001-09-10 | 2016-11-30 | Tibotec Pharm Ltd | Sposób syntezy heksahydrofuro [2,3-b] furan -3-olu oraz związki pośrednie stosowane w tym sposobie |
| PL371511A1 (en) | 2002-01-16 | 2005-06-27 | Solvay Pharmaceuticals B.V. | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds |
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| WO2004062692A1 (en) * | 2003-01-13 | 2004-07-29 | Solvay Pharmaceuticals B.V. | Formulation of poorly water-soluble active substances |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| AR046454A1 (es) * | 2003-11-18 | 2005-12-07 | Solvay Pharm Gmbh | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| MX2007006279A (es) | 2004-12-15 | 2007-06-14 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa. |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| US20070292503A1 (en) * | 2006-06-16 | 2007-12-20 | Gorissen Henricus R | Oral pharmaceutical composition of poorly water-soluble active substance |
| US20070299054A1 (en) * | 2006-06-22 | 2007-12-27 | Rajesh Jain | Oral pharmaceutical composition of a poorly water-soluble active agent |
| DK2247297T3 (en) * | 2008-01-31 | 2019-03-11 | Univ Vanderbilt | THERAPEUTIC TREATMENT OF LUNG CONDITIONS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| CA1337400C (en) * | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US5087702A (en) * | 1991-01-30 | 1992-02-11 | Merck & Co., Inc. | Microbial transformation process for producing an antihypertensive product |
| US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
-
1999
- 1999-02-16 DE DE19906310A patent/DE19906310A1/de not_active Ceased
-
2000
- 2000-01-20 AR ARP000100257A patent/AR036864A1/es unknown
- 2000-01-21 TW TW089101041A patent/TWI221770B/zh not_active IP Right Cessation
- 2000-02-10 PT PT00903681T patent/PT1154777E/pt unknown
- 2000-02-10 DE DE50010284T patent/DE50010284D1/de not_active Expired - Lifetime
- 2000-02-10 PL PL00350167A patent/PL195283B1/pl not_active IP Right Cessation
- 2000-02-10 HU HU0105491A patent/HUP0105491A3/hu unknown
- 2000-02-10 BR BR0008260-0A patent/BR0008260A/pt not_active Application Discontinuation
- 2000-02-10 CZ CZ20012672A patent/CZ301499B6/cs not_active IP Right Cessation
- 2000-02-10 CN CNB008038236A patent/CN1198619C/zh not_active Expired - Fee Related
- 2000-02-10 AU AU25476/00A patent/AU773240C/en not_active Ceased
- 2000-02-10 SK SK1082-2001A patent/SK287254B6/sk not_active IP Right Cessation
- 2000-02-10 KR KR1020077001387A patent/KR100797665B1/ko not_active Expired - Fee Related
- 2000-02-10 NZ NZ514058A patent/NZ514058A/en not_active IP Right Cessation
- 2000-02-10 WO PCT/EP2000/001068 patent/WO2000048601A1/de not_active Ceased
- 2000-02-10 RU RU2001124604/15A patent/RU2270679C2/ru not_active IP Right Cessation
- 2000-02-10 EP EP00903681A patent/EP1154777B1/de not_active Expired - Lifetime
- 2000-02-10 HK HK02104121.2A patent/HK1042247B/zh not_active IP Right Cessation
- 2000-02-10 ES ES00903681T patent/ES2238268T3/es not_active Expired - Lifetime
- 2000-02-10 JP JP2000599393A patent/JP2002537258A/ja active Pending
- 2000-02-10 TR TR2001/02386T patent/TR200102386T2/xx unknown
- 2000-02-10 CA CA2362273A patent/CA2362273C/en not_active Expired - Fee Related
- 2000-02-10 KR KR1020017009705A patent/KR20010101922A/ko not_active Ceased
- 2000-02-10 AT AT00903681T patent/ATE295174T1/de active
- 2000-02-13 DZ DZ000029A patent/DZ3014A1/xx active
- 2000-10-02 UA UA2001096336A patent/UA63032C2/uk unknown
-
2001
- 2001-07-16 ZA ZA200105828A patent/ZA200105828B/en unknown
- 2001-07-30 IL IL144622A patent/IL144622A/en not_active IP Right Cessation
- 2001-08-15 NO NO20013958A patent/NO329588B1/no not_active IP Right Cessation
- 2001-08-16 US US09/930,186 patent/US6482820B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002537258A5 (enExample) | ||
| US5393772A (en) | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation | |
| EP0498069B1 (en) | New use of peptide derivative | |
| US4703038A (en) | Combination of dihydropyridines with angiotensin converting enzymes-inhibitors | |
| HU199302B (en) | Process for producing synergic pharmaceutical compositions having hypotensive activity | |
| KR100797665B1 (ko) | 고혈압 치료를 위한 약제학적 조성물 | |
| JPH04234817A (ja) | オメプラゾールの直腸投与組成物 | |
| RU2268727C2 (ru) | Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений | |
| JP2005501825A5 (enExample) | ||
| US4859665A (en) | Antihypertensive combination products containing a dihydropyridine and a pyridazodiazepine | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| WO1994005290A1 (fr) | Inhibiteur d'agregation plaquettaire | |
| JPS6045518A (ja) | 抗シヨツク剤 | |
| WO2000013707A1 (en) | Preventives/remedies for multiple organ failure | |
| JPS61155327A (ja) | ジヒドロピリジン化合物を含有する抗動脈硬化剤 | |
| JP2618195B2 (ja) | 血中脂質代謝改善剤 | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| JPWO1993005778A1 (ja) | 血中脂質代謝改善剤 | |
| SE465751B (sv) | Farmaceutiskt preparat innehaallande co-dergocrin och en kalciumantagonist | |
| US5455257A (en) | Lacidipine for the treatment of arteriosclerosis | |
| JP2665564B2 (ja) | 細胞防護剤 | |
| JPS63107926A (ja) | 血中脂質改善剤 | |
| JPH0539226A (ja) | サイトメガロウイルス感染症用薬剤 | |
| JP3386873B2 (ja) | 消化器系疾患用剤 | |
| JPH03218313A (ja) | 脳細胞保護剤 |